The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Appointment

14 Mar 2013 07:00

RNS Number : 9595Z
Venn Life Sciences Holdings PLC
14 March 2013
 



Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Board Appointment

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Paul Kennedy as Non-Executive Director with immediate effect.

 

Paul has an extensive career in the pharmaceutical industry having been President of Novo Nordisk France for 15 years and before that working as a Marketing Director for seven years at Abbot France and Boots, both in the UK and France. Having left Novo Nordisk in 1994, Paul set up his own pharmaceutical company, Laboratoires Murat, which was purchased by Fuisz Technologies Ltd, a Nasdaq listed drug delivery company three years later. Paul then worked as Executive Vice President, Operations for Fuisz Technologies in Paris before the business was sold to Shire plc in 1999 for a further premium.

 

From 1999 to 2004 Paul worked as an Independent Consultant in the pharmaceutical industry where he continued to build on his M&A experience by advising on a series of transactions, including the sale of Ethypharm for €235m and the sale of Laboratoires Dexo for €12.5m. In 2004 Paul became President of International Operations at AIM listed medical diagnostics company Cozart plc, establishing their international organisation from a standing start. Cozart was subsequently sold for £65m in 2007 to Concateno plc. In 2007 Paul became a controlling shareholder and Director of US listed IVAX Diagnostics, Inc, which was subsequently sold to Transasia Bio-Medicals Ltd, India's largest diagnostics company, in September 2010. Paul is also fluent in French and Spanish.

 

Commenting on the appointment, Venn CEO, Tony Richardson, said: "We are very pleased to welcome Paul to the Board as a Non-Executive Director. Paul's knowledge of the pharmaceutical and medical diagnostics industries, and particularly his experience in M&A transactions, will be a great benefit to Venn as we continue to execute our strategy of becoming a leading mid-sized CRO in Europe."

 

Enquiries:

 

Venn Life Sciences Holdings Plc

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Paul Foulger, Finance Director

Tel: 020 7245 1100

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones(Corporate Finance)

Tel: 0161 831 1512

John Goold (Institutional Sales)

Tel: 020 7016 8925

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

Additional Information:

 

Paul Francis Kennedy, aged 68, holds 480,035 shares in the Company and other than as set out below there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Mr Kennedy's appointment today as a Director of the Company.

 

Paul is a director / partner or has been a director / partner of the following companies / partnerships during the previous five years:

 

Current directorships/partnerships

Director/Partner in the last 5 years

None

IVAX Diagnostics, Inc

 

 

About Venn Life Sciences Limited: www.vennlifesciences.com

 

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device organisations and having operations in France, the Netherlands, Russia and Ireland, with a branch office in Switzerland. The Venn Group also includes a Clinical Resourcing business based in France. The Company's near term objective is the expansion of its coverage to other European countries through strategic acquisitions thus combining a number of small European CROs to build a mid-sized CRO focused on the European market, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADXLFFXXFXBBD
Date   Source Headline
25th Oct 20227:00 amRNSChange of name to hVIVO plc effective
20th Oct 20227:00 amRNSCapital Markets Day
18th Oct 20227:00 amRNSCFO appointment & change of Board roles
30th Sep 20227:00 amRNSPositive in vitro results for FLU-v published
29th Sep 20229:30 amRNSDirector dealings
27th Sep 20227:00 amRNSUpcoming Scientific Presentations
15th Sep 20227:00 amRNSComment regarding press speculation
8th Sep 20227:01 amRNSInterim results and trading update
8th Sep 20227:00 amRNSIntention to change name to hVIVO plc
1st Sep 20227:20 amRNSCAP accreditation
25th Aug 20227:00 amRNSNotice of results
22nd Aug 20227:00 amRNS£10.4m contract with existing Big Pharma client
4th Aug 20227:00 amRNS£6.2m Influenza human challenge study contract
5th Jul 20221:17 pmRNSResult of AGM
30th Jun 20227:00 amRNSOmicron human challenge model
14th Jun 20227:00 amRNS£7.2m RSV human challenge study contract
10th Jun 202212:13 pmRNSBoard appointment amendment
10th Jun 202212:00 pmRNSAnnual Report and Notice of AGM
8th Jun 20227:00 amRNSBoard appointment
7th Jun 20229:05 amRNSSecond Price Monitoring Extn
7th Jun 20229:00 amRNSPrice Monitoring Extension
7th Jun 20227:00 amRNSFinal results
1st Jun 20227:00 amRNSGBP14.7m influenza contract signed
26th May 20227:00 amRNSCompletion of Nominated Adviser due diligence
24th May 20227:00 amRNSNotice of results
18th May 20227:00 amRNS£7.3m Influenza human challenge study contract win
12th May 20227:00 amRNSWellcome publication
5th May 20227:00 amRNSVaccine field study contract
4th May 20227:00 amRNSChallenge virus manufacturing contract
4th May 20227:00 amRNSComment re: speculation
28th Apr 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
13th Apr 20227:00 amRNSProposal to Distribution in Specie Shareholders
12th Apr 202212:00 pmRNSPresentation at World Vaccine Congress
6th Apr 20224:35 pmRNSPrice Monitoring Extension
6th Apr 20222:05 pmRNSSecond Price Monitoring Extn
6th Apr 20222:01 pmRNSPrice Monitoring Extension
6th Apr 202211:05 amRNSSecond Price Monitoring Extn
6th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 202210:05 amRNSCharacterisation Study results in Nature Medicine
25th Mar 20227:00 amRNS£5m RSV human challenge study contract win
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:37 pmRNSPrice Monitoring Extension
8th Mar 20227:00 amRNSTrading Update and screening facilities expansion
7th Mar 20222:06 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 202211:06 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSInvestor Presentations
24th Feb 20227:00 amRNSCEO Appointment
22nd Feb 20227:00 amRNSFDA Breakthrough Designation for Big Pharma RSV

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.